Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
tyrosine kinases needed for angiogenesis and cell growth. It is not yet known whether
sunitinib malate is effective as maintenance therapy in delaying tumor progression in
patients with metastatic pancreatic cancer who are progression-free after 6 months of
induction chemotherapy.
PURPOSE: This randomized phase II trial is studying sunitinib malate as maintenance therapy
to see how well it works compared with observation in avoiding tumor progression after
induction chemotherapy in patients with metastatic pancreatic cancer.